NeuroOne Medical Technologies Corp (NMTC)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$1.62-2.41%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · NMTC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -69.6% |
| Our one-year growth estimate | diamond | 30.8% |
Growth built into the price is above our model estimate.
The price assumes 100.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
NMTC — earnings miss
Dated 2026-08-13
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in…
Why it matters: The amendment will clarify the financial results and impact investor trust. A clear statement can stabilize the stock.
Supportive ifThe company files the amended Form 10-Q with no further revenue adjustments.
Worry ifThe change shows more problems with revenue or issues in financial reports.
Why it matters: The health care sector is maturing. Changes in revenue growth can impact NMTC's performance and outlook.
Watch forHealth care sector revenue growth re-accelerates back toward its highs.
Also watch forHealth care sector revenue growth continues to decelerate.
Why it matters: Meeting this target would show strong sales growth and support the $10.5 million annual goal.
Supportive ifQ2 product revenue reported at or above $2.4 million.
Worry ifQ2 product revenue was below $2.4 million. This shows ongoing sales problems.
Why it matters: The change will make financial results clearer. This will help investors trust the company.
Worry ifThe company will file the updated Form 10-Q. It will have corrected financial statements by June 30, 2026.
Less concerning ifThe company fails to file the amendment by the end of June 2026.
Why it matters: The debt issuance could impact the company's cash flow and future investments. Investors will want to see how it affects financial health.
Watch forA press release detailing the terms and expected use of proceeds from the debt issuance.
Also watch forNo further information released about the debt issuance or its terms.
Why it matters: If product orders exceed recognized revenue, it indicates strong demand and a growing backlog. This is a positive sign for future sales.
Supportive ifProduct orders are reported at $2.7 million. This is more than recognized revenue of $2.0 million.
Worry ifProduct orders fall below recognized revenue in the next quarter.
Why it matters: The earnings report will show how much money the company makes. This helps us see how well it can grow.
Watch forThe earnings report shows that revenue growth is speeding up again. This is better than last quarter.
Also watch forThe earnings report shows that revenue is still going down or not changing. This is a concern.
Why it matters: More product orders show strong demand and future revenue. It shows the company's market strength and customer trust.
Supportive ifTotal product orders for fiscal 2026 exceed $11.2 million.
Worry ifIf product orders drop below $11.2 million, it shows weak demand.
Why it matters: High product orders show strong demand. This means more money in the future.
Supportive ifProduct orders exceed recognized revenue for two quarters in a row.
Worry ifProduct orders fall below recognized revenue for two quarters in a row.
Why it matters: This certification allows sales in other countries. It shows the company meets high-quality standards. This is important for growth in new markets.
Supportive ifISO 13485 certification will be received by the end of fiscal 2026.
Worry ifISO 13485 certification is not received by the end of fiscal 2026.
Why it matters: Achieving this revenue shows the company is on track for its annual growth goal. It reflects overall business health.
Supportive ifTotal revenue for fiscal 2026 reported at or above $10.5M.
Worry ifTotal revenue for fiscal 2026 reported below $10.5M.
Why it matters: This launch is crucial for expanding the product line and revenue streams.
Supportive ifThe company will launch the drug delivery system in the second half of 2026.
Worry ifThe launch is delayed or canceled. This may mean there are operational problems.
Why it matters: The outcome of this event may affect investor trust and financial reporting. Clarity is needed.
Worry ifThe legal event is resolved. No more issues have been reported.
Less concerning ifThere are new problems or bad news about the legal event.
Why it matters: Hitting this revenue target shows the company's growth and market demand for its products. It confirms management's strategy is working.
Supportive ifProduct revenue reported at $10.5 million or more for fiscal 2026.
Worry ifProduct revenue falls below $10.5 million for fiscal 2026.
Why it matters: Launching this platform expands NeuroOne's offerings and could drive future revenue growth. It reflects progress in product development.
Supportive ifThe StereoCED platform will be ready for studies by the end of fiscal 2026.
Worry ifLaunch of the StereoCED platform is delayed beyond fiscal 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$303 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $836 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,610 loss on $10,000 · 76.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.